Navigation Links
Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
Date:1/17/2013

d to announce that the first patients are now enrolled in our Phase 3 HCVerso™ program, including at U.S. trial sites," said Peter Piliero , M.D., Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Patients infected with HCV may benefit most from an individualized treatment approach since a person's genetics, type of virus, and stage of liver disease vary from patient to patient. Our investigational interferon-free regimen has shown particular promise in treating patients with HCV genotype-1b so we have decided to enroll these patients in our Phase 3 trial program. Our goal is for an interferon-free future and ensuring patients are treated with the most effective treatment for them individually."

Results from the SOUND-C2 study, which were presented in November 2012 at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), found that up to 85 percent of patients infected with HCV GT-1b treated with Boehringer Ingelheim's investigational IFN-free regimen of faldaprevir, BI 207127 and ribavirin achieved viral cure at 12 and 24 weeks following treatment completion (SVR12 and SVR24).

Eliminating injectable interferon from treatment regimens is a critical goal in HCV as it can be difficult for patients to take due to long treatment duration and often severe side-effects. In addition, up to 50 percent of patients may not be eligible for treatment with interferon. Severe side-effects of interferon include heart failure, sepsis, leukopenia, depression and vision loss, resulting in adherence problems and treatment failure for many patients. Since 1999 there has been a significant increase in deaths due to chronic HCV, accounting for 15,000 deaths in the United States in 2007 alone.

"More effective and tolerable alternatives to interferon would help patients with their decision to start and
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
2. Boehringer Ingelheim Announces Equine Research Awards
3. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
4. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
5. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
6. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
7. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
8. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
9. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
10. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
11. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Leading events organizer UBM Live announces that CPhI ... São Paulo, Brazil from 5 th ... co-locate with Food Ingredients South America (FiSA), creating ... pharmaceutical industry.      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) Three ... exploring the South America market as ...
(Date:7/24/2014)... CITY, Calif. , July 24, 2014   ... specialty pharmaceutical company focused on the development and commercialization ... breakthrough pain, today confirmed the PDUFA date for Zalviso ... learned that a rumor circulated online stating the Food ... July 24, 2014 there has been no notification to ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Calif., Oct. 11 Threshold,Pharmaceuticals, Inc. (Nasdaq: THLD ... analysis, it would stop enrollment in a Phase 2 ... patients with,recurrent, sensitive small cell lung cancer. The ... there would be,an adequate response rate to justify complete ...
... KineMed Inc., a,pathway-based drug discovery and development company, ... an investigational agent,to regenerate nerve cells in the ... and mood. The agent, part of a partnered ... behavioral test in a,preclinical model. The findings were ...
Cached Medicine Technology:Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 2Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 3KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3
(Date:7/25/2014)... CMS recently has imposed a series ... inadequate access to prescription drugs. Agency audits are uncovering ... safety of beneficiaries in areas such as rejected pharmacy ... is taking quick and firm actions to halt them. ... “Avoiding Costly Part D Sanctions: Rx Access Strategies ...
(Date:7/25/2014)... Wa (PRWEB) July 25, 2014 ... Pdf review recently updated by Vkool.com, this ... people how to treat some common types ... hemorrhoids and internal hemorrhoids ,     Young ... pregnancy with hemorrhoids ,     Very large ...
(Date:7/25/2014)... According to the Addict Him To You Pdf review ... that teaches women how to get the love of the ... review that this book consists of 4 parts, including:, ... commit yet (and what to do about it) , ... ,     Part 3: How to touch his heart deeply ...
(Date:7/25/2014)... Silver®Care , for the first time in ... that naturally kill oral bacteria and airborne bacteria from the ... toothbrush is the most common and important device in the ... is subject to constant contamination by bacteria found in the ... in the mouth than anywhere else in the human body, ...
(Date:7/24/2014)... July 25, 2014 iFitDress.com, a renowned ... new range of casual party dresses . According ... party gowns are now offered at discounted prices, up ... this morning until August 04. , Most of ... in the global market. They are popular for special ...
Breaking Medicine News(10 mins):Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 3Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 3Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2
... Aug. 31 A new report,issued by the ... payments are 67 percent lower than anesthesia payments,from ... Anesthetists (CRNAs) are essential to ensuring that America,s ... pain management, and other,needed healthcare services., "Medicare ...
... of us hope our minds stay sharp,and active as ... simple as going to,the gym. Doctor Gary Small, a ... and aging, says the key to staying sharp is ... this report from Radica at:, http://media.medialink.com/WebNR.aspx?story=33787 Registered ...
... BlueCross BlueShield of South,Carolina has created a new ... Jill Davis to vice president in charge of ... to CEO M. Edward Sellers and is,responsible for ... formalizing a corporate-wide executive development program. "We ...
... Aug. 31 Lutheran Senior Services,(LSS), a leading ... that they provide the highest quality care and ... has partnered with Silverchair,Learning Systems to provide superior ... employees, beginning in January 2008. "Lutheran Senior ...
... Ill., Aug. 31 Landauer, Inc. (NYSE:,LDR) announced today ... dividend of $0.475 per share for the fourth quarter ... 5, 2007, to shareholders,of record on September 14, 2007. ... of analytical services to determine,occupational and environmental radiation exposure. ...
... World Heart,Corporation (WorldHeart) (Nasdaq: WHRT , ... today announced the appointment of,Mr. David Pellone as ... Juelis, the departing CFO, will provide consulting services,through ... the transition and with certain,specific projects. Mr. ...
Cached Medicine News:Health News:GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care 2Health News:S.C. BlueCross Creates Corporate Planning Unit, Promotes Davis to Vice President 2Health News:Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education 2Health News:Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education 3Health News:WorldHeart Appoints David Pellone Chief Financial Officer 2
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With reinforced ...
... with concave seats and large backrests with ... backrests, armrests, and casters and glides. • ... in a variety of environments including: industry, ... care and office. • With reinforced nylon ...
Medicine Products: